10x Genomics, Inc. (NASDAQ: TXG) is a biotech company that specializes in gene sequencing and in developing software for scientific data analysis. The company's name signifies its core mission of ushering in a new era of biology where researchers can explore and make new discoveries at a scale that is exponentially (10x) greater than the current capabilities.
Established in 2012, the Pleasanton, California-based company's innovative gene sequencing and data analysis tools have significantly impacted biological research, and are extensively utilized in the areas of oncology, immunology, neuroscience, and more. Its flagship technology, the Chromium platform, known for its ability to process a massive amount of biological data, is widely recognized as an industry game-changer. Accompanied by data analysis software, Cell Ranger and Loupe, these technologies have brought about a paradigm shift in genomics and single cell research.
The mission of 10x Genomics is to accelerate biological research for gaining new insights and driving radical improvements in health and treatment. Helping researchers understand the underlying mechanisms of complex diseases like cancer, Alzheimer's, and Covid-19 is a vital part of their mission.
In 2019, the company went public with an Initial public offering (IPO) on Nasdaq under the symbol 'TXG'. Its financial performance has been impressive, with its annual revenue seeing a consistent year-over-year growth which reflects the widespread acceptance and adoption of its technology in the scientific community.
10x Genomics has remained at the forefront of its industry by continually improving and investing in its product suite. For example, in 2020, the company acquired ReadCoor and CartaNA, both working on spatial genomics technologies. These acquisitions indicate the company's strategy to expand its product line and tap into the next stage of genomics - spatial genomics.
In essence, 10x Genomics is revolutionizing the field of genomics by allowing researchers to observe and investigate biological systems at an unparalleled scale. From developing advanced technology like the Chromium Next GEM Single Cell 3’/5’ and ATAC solution to fostering new partnerships and collaborations, 10x Genomics is one of the leading biotech companies pushing the boundaries of biological science and research. Its efforts play a crucial role in driving our understanding of biology and disease forward, and ultimately improving human health.